Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing Abiraterone (Zytiga®) Therapy by Exploring the Relation Between an Early Biomarker - Drug Exposure - as a Predictor for Drug Response in Patients With mCRPC

NCT02426333 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT02426333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02426333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing Abiraterone (Zytiga®) Therapy by Exploring the Relation Between an Early Biomarker - Drug Exposure - as a Predictor for Drug Response in Patients With mCRPC
Lead sponsor
Radboud University Medical Center
Phase
Observational
Overall status
Completed
Start date
January 31, 2016
Completion date
August 1, 2019
Enrollment
56 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration resistant prostate cancer